Published in Am J Hum Genet on November 17, 2003
The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med (2009) 3.05
Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 2.62
Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med (2010) 2.23
Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat Med (2009) 2.12
CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics (2007) 2.11
Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet (2008) 1.95
Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal (2010) 1.68
Recent insights into cerebral cavernous malformations: a complex jigsaw puzzle under construction. FEBS J (2010) 1.53
Cerebral cavernous malformation: new molecular and clinical insights. J Med Genet (2006) 1.52
Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. Dis Model Mech (2009) 1.49
Cavernous malformations: natural history, diagnosis and treatment. Nat Rev Neurol (2009) 1.47
CCM3 signaling through sterile 20-like kinases plays an essential role during zebrafish cardiovascular development and cerebral cavernous malformations. J Clin Invest (2010) 1.42
A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet (2010) 1.39
Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation. Nat Med (2016) 1.39
Biomedicine and diseases: the Klippel-Trenaunay syndrome, vascular anomalies and vascular morphogenesis. Cell Mol Life Sci (2005) 1.37
Crystal structure of CCM3, a cerebral cavernous malformation protein critical for vascular integrity. J Biol Chem (2010) 1.30
Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol (2004) 1.30
Developmental timing of CCM2 loss influences cerebral cavernous malformations in mice. J Exp Med (2011) 1.25
Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. J Biol Chem (2009) 1.23
From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet (2009) 1.23
Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mamm Genome (2006) 1.23
Deletions in CCM2 are a common cause of cerebral cavernous malformations. Am J Hum Genet (2006) 1.19
Apoptotic functions of PDCD10/CCM3, the gene mutated in cerebral cavernous malformation 3. Stroke (2009) 1.16
STRIPAK complexes: structure, biological function, and involvement in human diseases. Int J Biochem Cell Biol (2013) 1.13
Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis (2009) 1.12
Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery (2009) 1.10
Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology. Cell Mol Life Sci (2013) 1.08
CCM3 Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas. Mol Syndromol (2013) 1.03
Adaptor protein cerebral cavernous malformation 3 (CCM3) mediates phosphorylation of the cytoskeletal proteins ezrin/radixin/moesin by mammalian Ste20-4 to protect cells from oxidative stress. J Biol Chem (2012) 1.01
Cerebral cavernous malformation proteins at a glance. J Cell Sci (2014) 1.00
Emerging clinical imaging techniques for cerebral cavernous malformations: a systematic review. Neurosurg Focus (2010) 0.98
Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae. BMC Biotechnol (2007) 0.98
Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation (2014) 0.98
Structural basis for the disruption of the cerebral cavernous malformations 2 (CCM2) interaction with Krev interaction trapped 1 (KRIT1) by disease-associated mutations. J Biol Chem (2014) 0.96
Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling. Biol Chem (2013) 0.94
Different spectra of genomic deletions within the CCM genes between Italian and American CCM patient cohorts. Neurogenetics (2007) 0.94
Pathogenesis of vascular anomalies. Clin Plast Surg (2011) 0.93
CCM1 gene deletion identified by MLPA in cerebral cavernous malformation. Neurosurg Rev (2006) 0.93
Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med (2008) 0.93
Molecular recognition of leucine-aspartate repeat (LD) motifs by the focal adhesion targeting homology domain of cerebral cavernous malformation 3 (CCM3). J Biol Chem (2011) 0.93
CCM molecular screening in a diagnosis context: novel unclassified variants leading to abnormal splicing and importance of large deletions. Neurogenetics (2013) 0.93
CCM2-CCM3 interaction stabilizes their protein expression and permits endothelial network formation. J Cell Biol (2015) 0.92
Recent insights into cerebral cavernous malformations: animal models of CCM and the human phenotype. FEBS J (2010) 0.92
Vascular anomalies: from genetics toward models for therapeutic trials. Cold Spring Harb Perspect Med (2012) 0.91
High mutation detection rates in cerebral cavernous malformation upon stringent inclusion criteria: one-third of probands are minors. Mol Genet Genomic Med (2014) 0.91
Conditional deletion of Ccm2 causes hemorrhage in the adult brain: a mouse model of human cerebral cavernous malformations. Hum Mol Genet (2011) 0.91
Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum Mol Genet (2014) 0.91
Defining the functional domain of programmed cell death 10 through its interactions with phosphatidylinositol-3,4,5-trisphosphate. PLoS One (2010) 0.91
PDCD10/CCM3 acts downstream of {gamma}-protocadherins to regulate neuronal survival. J Biol Chem (2010) 0.90
Distinct functions for Rap1 signaling in vascular morphogenesis and dysfunction. Exp Cell Res (2013) 0.89
Clinical impact of CCM mutation detection in familial cavernous angioma. Childs Nerv Syst (2006) 0.88
Structural studies of cerebral cavernous malformations 2 (CCM2) reveal a folded helical domain at its C-terminus. FEBS Lett (2012) 0.87
PHACE syndrome is associated with intracranial cavernous malformations. Childs Nerv Syst (2016) 0.86
Arteriovenous malformations and other vascular malformation syndromes. Cold Spring Harb Perspect Med (2013) 0.85
Study of cerebral cavernous malformation in Spain and Portugal: high prevalence of a 14 bp deletion in exon 5 of MGC4607 (CCM2 gene). J Neurol (2007) 0.85
PTEN/PI3K/Akt/VEGF signaling and the cross talk to KRIT1, CCM2, and PDCD10 proteins in cerebral cavernous malformations. Neurosurg Rev (2014) 0.84
ccm2-like is required for cardiovascular development as a novel component of the Heg-CCM pathway. Dev Biol (2013) 0.84
KRIT1 protein depletion modifies endothelial cell behavior via increased vascular endothelial growth factor (VEGF) signaling. J Biol Chem (2014) 0.84
Mutation prevalence of cerebral cavernous malformation genes in Spanish patients. PLoS One (2014) 0.83
Cerebral cavernous malformations: from molecular pathogenesis to genetic counselling and clinical management. Eur J Hum Genet (2011) 0.82
Update on the molecular genetics of vascular anomalies. Lymphat Res Biol (2005) 0.82
Small deletion at the 7q21.2 locus in a CCM family detected by real-time quantitative PCR. J Biomed Biotechnol (2010) 0.82
Identification of two novel mutations and of a novel critical region in the KRIT1 gene. Neurogenetics (2006) 0.81
Long non-coding RNA expression profiles in hereditary haemorrhagic telangiectasia. PLoS One (2014) 0.80
Inherited cavernous malformations of the central nervous system: clinical and genetic features in 19 Swiss families. Neurosurg Rev (2009) 0.79
Network-based analysis of omics data: The LEAN method. Bioinformatics (2016) 0.77
Nogo-B receptor deficiency causes cerebral vasculature defects during embryonic development in mice. Dev Biol (2015) 0.77
Small GTPase Rap1 Is Essential for Mouse Development and Formation of Functional Vasculature. PLoS One (2015) 0.77
Sporadic cerebral cavernous malformations: report of further mutations of CCM genes in 40 Italian patients. Biomed Res Int (2013) 0.76
A mouse model of heritable cerebrovascular disease. PLoS One (2010) 0.76
Mechanisms of vascular stability and the relationship to human disease. Curr Opin Hematol (2010) 0.76
Introduction to cerebral cavernous malformation: a brief review. BMB Rep (2016) 0.76
Familial cerebral cavernous malformation: report of a further Italian family. Neurol Sci (2009) 0.76
Systems biology and proteomic analysis of cerebral cavernous malformation. Expert Rev Proteomics (2014) 0.76
Genetics of cerebral cavernous malformations: current status and future prospects. J Neurosurg Sci (2015) 0.76
A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. Am J Med Genet B Neuropsychiatr Genet (2016) 0.75
Cerebral Cavernous Malformations: Review of the Genetic and Protein-Protein Interactions Resulting in Disease Pathogenesis. Front Surg (2016) 0.75
The pathobiology of vascular malformations: insights from human and model organism genetics. J Pathol (2016) 0.75
Role of cytoskeletal proteins in cerebral cavernous malformation signaling pathways: a proteomic analysis. Mol Biosyst (2014) 0.75
A founder mutation in the Ashkenazi Jewish population affecting messenger RNA splicing of the CCM2 gene causes cerebral cavernous malformations. Genet Med (2011) 0.75
Familial cerebral cavernomas due to a KRIT1 mutation presenting with epilepsy. BMJ Case Rep (2011) 0.75
A Novel CCM2 Gene Mutation Associated with Familial Cerebral Cavernous Malformation. Front Aging Neurosci (2016) 0.75
Micro-CT Imaging Reveals Mekk3 Heterozygosity Prevents Cerebral Cavernous Malformations in Ccm2-Deficient Mice. PLoS One (2016) 0.75
CCM3/SERPINI1 bidirectional promoter variants in patients with cerebral cavernous malformations: a molecular and functional study. BMC Med Genet (2016) 0.75
CCM1 and the second life of proteins in adhesion complexes. Cell Adh Migr (2014) 0.75
Structural analysis of the KRIT1 ankyrin repeat and FERM domains reveals a conformationally stable ARD-FERM interface. J Struct Biol (2015) 0.75
Vascular heterogeneity and specialization in development and disease. Nat Rev Mol Cell Biol (2017) 0.75
Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies. Semin Intervent Radiol (2017) 0.75
Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet (1999) 3.15
The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg (1994) 3.06
Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med (1988) 2.65
Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene (1997) 2.31
KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet (2002) 2.28
Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet (1998) 2.16
Interaction between krit1 and icap1alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum Mol Genet (2001) 2.07
A gene responsible for cavernous malformations of the brain maps to chromosome 7q. Hum Mol Genet (1995) 1.74
ICAP-1, a novel beta1 integrin cytoplasmic domain-associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. J Cell Biol (1997) 1.72
Vascular morphogenesis: tales of two syndromes. Hum Mol Genet (2003) 1.69
KRIT1, a gene mutated in cerebral cavernous malformation, encodes a microtubule-associated protein. Proc Natl Acad Sci U S A (2002) 1.57
Angiographically occult vascular malformations: a correlative study of features on magnetic resonance imaging and histological examination. Neurosurgery (1994) 1.45
Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21. Proc Natl Acad Sci U S A (1995) 1.43
Krit1/cerebral cavernous malformation 1 mRNA is preferentially expressed in neurons and epithelial cells in embryo and adult. Mech Dev (2002) 1.27
Interaction of the integrin beta1 cytoplasmic domain with ICAP-1 protein. J Biol Chem (1999) 1.25
Pathology of cerebral vascular malformations. Neurosurg Clin N Am (1999) 1.23
A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics (1995) 1.15
Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1). Acta Neuropathol (2002) 1.09
Linkage to the CCM2 locus and genetic heterogeneity in familial cerebral cavernous malformation. Can J Neurol Sci (2003) 0.99
Bodenin: a novel murine gene expressed in restricted areas of the brain. Dev Dyn (1998) 0.98
Genetic heterogeneity and absence of founder effect in a series of 36 French cerebral cavernous angiomas families. Eur J Hum Genet (1999) 0.97
Familial cavernous angiomas of the brain: observations in a four generation family. Eur J Pediatr (1992) 0.95
Familial cerebral cavernous angioma: clinical analysis of a family and phenotypic classification. Epilepsy Res (1995) 0.89
Cavernous angiomas of the nervous system in Italy: clinical and genetic study. Neurol Sci (2000) 0.89
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet (2008) 9.51
Variation in genome-wide mutation rates within and between human families. Nat Genet (2011) 8.84
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med (2013) 4.26
Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet (2011) 4.01
Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N Engl J Med (2009) 3.88
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet (2010) 3.69
Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet (2009) 3.33
De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A (2010) 3.13
The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med (2009) 3.05
Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet (2003) 3.02
A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet (2002) 2.98
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet (2004) 2.97
Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat Genet (2006) 2.92
Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch Neurol (2007) 2.89
Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet (2011) 2.86
A quantitative trait locus (LSq-1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia. Circulation (2008) 2.77
Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann Neurol (2007) 2.76
Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet (2002) 2.72
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA (2005) 2.59
CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet (2005) 2.52
Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet (2009) 2.43
Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet (2009) 2.40
Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development (2004) 2.35
Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet (2009) 2.31
Exome sequencing identifies FUS mutations as a cause of essential tremor. Am J Hum Genet (2012) 2.30
KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet (2002) 2.28
Mutations in SYNE1 lead to a newly discovered form of autosomal recessive cerebellar ataxia. Nat Genet (2006) 2.17
Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med (2006) 2.13
Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta (2006) 2.05
A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med (2010) 2.00
Genetics of familial amyotrophic lateral sclerosis. Neurology (2008) 2.00
Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet (2003) 2.00
SWAN MRI revealing multiple microhemorrhages secondary to septic emboli from mucormycosis. Neurology (2012) 1.97
Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology (2002) 1.96
Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet (2008) 1.95
Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet (2011) 1.94
Novel RPGR mutations with distinct retinitis pigmentosa phenotypes in French-Canadian families. Am J Ophthalmol (2003) 1.93
Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis (2006) 1.92
Mutations in the KIAA0196 gene at the SPG8 locus cause hereditary spastic paraplegia. Am J Hum Genet (2006) 1.92
Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke (2011) 1.91
Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board. Stroke (2008) 1.87
Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med (2006) 1.83
De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. Am J Hum Genet (2010) 1.79
Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One (2009) 1.78
Disruption at the PTCHD1 Locus on Xp22.11 in Autism spectrum disorder and intellectual disability. Sci Transl Med (2010) 1.75
TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet (2011) 1.75
Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. Am J Hum Genet (2004) 1.70
Vascular morphogenesis: tales of two syndromes. Hum Mol Genet (2003) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic? J Neurol Neurosurg Psychiatry (2010) 1.68
DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J Biol Chem (2006) 1.68
KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am J Hum Genet (2011) 1.66
Mutations in the calcium-related gene IL1RAPL1 are associated with autism. Hum Mol Genet (2008) 1.66
A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet (2001) 1.65
Common variants in P2RY11 are associated with narcolepsy. Nat Genet (2010) 1.65
Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet (2009) 1.63
Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep (2009) 1.62
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Mutations in the nervous system--specific HSN2 exon of WNK1 cause hereditary sensory neuropathy type II. J Clin Invest (2008) 1.61
NLGN3/NLGN4 gene mutations are not responsible for autism in the Quebec population. Am J Med Genet B Neuropsychiatr Genet (2005) 1.60
A role for Orai in TRPC-mediated Ca2+ entry suggests that a TRPC:Orai complex may mediate store and receptor operated Ca2+ entry. Proc Natl Acad Sci U S A (2009) 1.57
Cerebral cavernomas in the adult. Review of the literature and analysis of 72 surgically treated patients. Neurosurg Rev (2002) 1.53
Redefining heart failure: the utility of genomics. J Am Coll Cardiol (2006) 1.52
The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum. Nat Genet (2002) 1.51
The impact of phenotypic and genetic heterogeneity on results of genome wide association studies of complex diseases. PLoS One (2013) 1.51
Mutations in SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing haploinsufficiency. Hum Mutat (2012) 1.50
Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer (2002) 1.49
The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum Mol Genet (2003) 1.49
Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am J Med Genet A (2010) 1.49
FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet (2011) 1.46
A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet (2007) 1.46
Effective surgical treatment of cerebral cavernous malformations: a multicenter study of 79 pediatric patients. J Neurosurg Pediatr (2011) 1.45
Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI. J Magn Reson Imaging (2003) 1.45
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain. J Cereb Blood Flow Metab (2004) 1.44
Tnni3k modifies disease progression in murine models of cardiomyopathy. PLoS Genet (2009) 1.44
Allelic mutations of the sodium channel SCN8A reveal multiple cellular and physiological functions. Genetica (2004) 1.43
C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain (2013) 1.42
De novo STXBP1 mutations in mental retardation and nonsyndromic epilepsy. Ann Neurol (2009) 1.41
Mutations in DCC cause congenital mirror movements. Science (2010) 1.41
A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet (2010) 1.39
Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke (2004) 1.39
Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry (2005) 1.39
A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet (2003) 1.38
Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain (2011) 1.33
Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem (2009) 1.33
Mutations in C5ORF42 cause Joubert syndrome in the French Canadian population. Am J Hum Genet (2012) 1.32
Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet (2006) 1.30
What's the problem with generic antiepileptic drugs?: a call to action. Neurology (2007) 1.30
Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol (2004) 1.30
Array comparative genomic hybridization in patients with congenital diaphragmatic hernia: mapping of four CDH-critical regions and sequencing of candidate genes at 15q26.1-15q26.2. Eur J Hum Genet (2006) 1.29
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet (2005) 1.29